Literature DB >> 6102647

Antithrombin III deficiency during asparaginase therapy.

E Vellenga, N H Mulder, H O Nieweg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6102647     DOI： 10.1016/s0140-6736(80)91139-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.

Authors:  David Hernández-Espinosa; Antonia Miñano; Constantino Martínez; Elena Pérez-Ceballos; Inmaculada Heras; José L Fuster; Vicente Vicente; Javier Corral
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  Combination chemotherapy for acute lymphocytic leukaemia in 25 adults.

Authors:  E G de Vries; N H Mulder; B Houwen; H Haaxma-Reiche
Journal:  Blut       Date:  1982-03

3.  A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

Authors:  John L Hays; Geoff Kim; Amanda Walker; Christina M Annunziata; Jung-Min Lee; Jennifer Squires; Nicole Houston; Seth M Steinberg; Elise C Kohn
Journal:  Mol Clin Oncol       Date:  2013-03-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.